Intradialytic versus home based exercise training in hemodialysis patients: a randomised controlled trial by Koh, Kirsten P et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Nephrology
Open Access Study protocol
Intradialytic versus home based exercise training in hemodialysis 
patients: a randomised controlled trial
Kirsten P Koh1, Robert G Fassett2,3,4,5, James E Sharman5, Jeff S Coombes2,3 
and Andrew D Williams*1
Address: 1School of Human Life Sciences, University of Tasmania, Newnham, Tasmania 7250, Australia, 2School of Human Movement Studies, 
The University of Queensland, St Lucia, Queensland 4072, Australia, 3Renal Research Tasmania, Launceston General Hospital, Charles St 
Launceston, Tasmania 7005, Australia, 4Renal Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland 4029, Australia and 
5School of Medicine, University of Queensland, Brisbane, Queensland 4029, Australia
Email: Kirsten P Koh - kirsten_koh@rp.sg; Robert G Fassett - rfassett@mac.com; James E Sharman - j.sharman@uq.edu.au; 
Jeff S Coombes - jcoombes@hms.uq.edu.au; Andrew D Williams* - Andrew.Williams@utas.edu.au
* Corresponding author    
Abstract
Background: Exercise training in hemodialysis patients improves fitness, physical function, quality
of life and markers of cardiovascular disease such as arterial stiffness. The majority of trials
investigating this area have used supervised exercise training during dialysis (intradialytic), which
may not be feasible for some renal units. The aim of this trial is to compare the effects of supervised
intradialytic with unsupervised home-based exercise training on physical function and arterial
stiffness.
Methods and design: This is a randomised, controlled clinical trial. A total of 72 hemodialysis
patients will be randomised to receive either six months of intradialytic exercise training, home-
based exercise training or usual care. Intradialytic patients will undergo three training sessions per
week on a cycle ergometer and home-based patients will be provided with a walking program to
achieve the same weekly physical activity. Primary outcome measures are six-minute walk distance
(6 MWD) and aortic pulse wave velocity (PWV). Secondary outcome measures include
augmentation index, peripheral and central blood pressures, physical activity and self-reported
health. Measures will be made at baseline, three and six months.
Discussion: The results of this study will help determine the efficacy of home-based exercise




A number of studies have shown that intradialytic exercise
training has positive effects on patients, such as improving
cardiorespiratory fitness, physical function and self-
reported health [1]. Less work has focussed on the effects
of exercise training on cardiovascular risk factors in dialy-
sis patients although some evidence suggests improve-
ments in fasting glucose and insulin, an enhancement in
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the management of hypertension, and a reduction in
inflammation [2-5].
Cardiovascular pathologies observed in ESKD patients
include left ventricular hypertrophy and arterial disease
[6]. In addition to the characteristic lesions of atheroscle-
rosis, dialysis patients also experience thickening and
fibrosis of the arterial wall in response to pressure and vol-
ume overload, loss of elastic fibres and medial fibrosis [7].
Such arterial remodelling, along with medial calcification,
causes arteries to stiffen, thereby exacerbating left ven-
tricular dysfunction [8]. Indeed, widening of the pulse
pressure, the simplest and crudest method of assessing
arterial stiffness, has proven to be a better marker of mor-
tality than systolic pressure in haemodialysis patients [9].
Stiffening also results in more rapid propagation of the
arterial pulse pressure wave through the conductance
arteries and can be readily assessed by measuring aortic
pulse wave velocity (PWV; a marker of regional large
artery stiffness) and central augmentation index (AIx; a
composite marker of systemic arterial stiffness and left
ventricular systolic loading). Indeed, there is a clear evi-
dence base that measures of arterial stiffness are inde-
pendent predictors of cardiovascular morbidity and
mortality in different patient populations [10] but partic-
ularly in ESKD patients [11-13].
To date, to our knowledge, only two studies have investi-
gated the effect of exercise training on arterial stiffness in
ESKD [14,15]. In an uncontrolled study of 11 hemodialy-
sis patients, Mustata and coworkers [14] found a signifi-
cant improvement in AIx after three months of supervised
exercise training. More recently, aortic PWV was signifi-
cantly decreased following three months of intradialytic
exercise in 19 hemodialysis patients [15].
The majority of studies investigating the effects of exercise
in dialysis patients have used supervised intradialytic exer-
cise training. These programs are resource intensive which
may preclude their use in clinical practice. Consequently
other interventions should be investigated. To our knowl-
edge only one study has compared different training regi-
mens in an attempt to optimize the benefits of exercise
training in ESKD patients [16]. Therefore, the aims of this
study are to compare the effects of supervised intradialytic
or unsupervised home-based exercise training on arterial
stiffness and physical function in hemodialysis patients.
Methods
Study design and setting
The study is a multi-centre, randomized controlled trial in
hemodialysis patients. The study will be conducted at the
Launceston General Hospital and Burnie Satellite Renal
Units in Northern Tasmania and the Hobart Renal Unit,
which, combined, service a population of approximately
485,000.
Ethical considerations
The Tasmanian Statewide Scientific and Ethics Commit-
tees have approved the trial. The Ethics Committee will be
provided with annual reports of the trial progress and will
promptly receive all adverse event reports. A condition of
ethical approval requires investigators to provide bro-
chures to all hemodialysis patients at each of the sites
indicating the benefits of exercise in end stage kidney dis-
ease. Hence, potential benefits of regular exercise will be
made known to patients regardless of their decision to
participate in the study or the group to which they are ran-
domised.
Identification of eligible patients
Patients who commence and/or maintain dialysis for at
least three-months will be approached to participate in
this study. Eligible patients will receive a copy of the
patient information sheet placed in the medical record.
The principal investigator will then explain the study dur-
ing a clinical consultation. After the explanation the sub-
jects will be provided with a patient information sheet
and informed consent form. The subject will then be
asked to take this away with them and make a decision
before their next hemodialysis visit. If the subject agrees to
participate, they will sign the consent form with an inde-
pendent person signing as a witness.
Eligibility
Inclusion criteria are; age >18 and < 85 years incident and/
or prevalent dialysis patients. Subjects will be excluded if
they have unstable angina, lower limb amputation, or if
they already meet or exceed the exercise recommendation
of 120 minutes of moderate intensity physical activity per
week[17] Subjects will also be excluded if they are partic-
ipating in, or propose to participate in, another clinical
intervention study within 30 days prior to study entry.
Randomization
An individual not associated with the trial will perform
the randomization using a computer generated random
number system.
Interventions
Intradialytic training requires participants to train on cycle
ergometers (Rehab Trainer 881E, Monark, Sweden)
within the first two hours of each dialysis session, three
times per week for 6 months. Intensity will be individual-
ised on the basis of perceived exertion, exercise heart rate
and blood pressure. Participants will be requested to exer-
cise at an RPE of 12–13 on the Borg 6–20 scale [18]. In
cases where patients' training heart rates are low at a
reported RPE of 12–13, the supervisor will increase theBMC Nephrology 2009, 10:2 http://www.biomedcentral.com/1471-2369/10/2
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resistance to elicit a greater cardiorespiratory response.
However, patients will be permitted to stop and rest or
request to train at a lower intensity. In the event that exer-
cise blood pressure exceeds predetermined safe levels for
the participant, (>200/110 mmHg) they will be instructed
to temporarily cease exercise and will be monitored until
blood pressure returns to safe levels. Patients on medica-
tions that affect cardiac sinus rhythm will be trained
strictly according to reported RPE. Over the duration of
the exercise intervention, supervisors will periodically
increase the resistance of the ergometer to maintain RPE.
While participants will be encouraged to start and
progress the duration of exercise according to their indi-
vidual capabilities, a general guideline used by investiga-
tors will be for participants to complete fifteen minutes of
exercise per session in the first two weeks of the interven-
tion, progress to thirty minutes of exercise per session by
week 12 and to forty-five minutes by week 24. Power out-
put (w) and duration (minutes) of each exercise session
will be recorded to estimate participants' individual
energy expenditure per session during the training period.
Home-based participants will be asked to perform thrice
weekly unsupervised walking for six months at perceived
exertions of 12–13 on the Borg 6–20 scale. To ensure a
similar treatment to the intradialytic group's training
duration, home-based participants will be requested to
start and progress their walking program according to
individual capabilities however investigators will encour-
age participants to start at fifteen minutes per session for
the first two weeks and to progress to 30 minutes by week
12 and to forty-five minutes by week 24 as per the ID
group. Participants will be phoned fortnightly to provide
encouragement and to allow feedback on progress. Only
the duration and number of steps of each walking session
will be monitored and, therefore, an adequate estimation
of total energy expended will not be performed. However,
HB participants will be encouraged to regularly increase
intensity by walking faster or walking on routes with some
degree of incline. Usual care participants will be requested
to maintain their usual daily activities and will be
reminded of the importance of this regularly throughout
the study.
Once randomised, participants will undergo a series of
tests including physical function and arterial stiffness
measurements at baseline, three months, and six months.
All participants will be instructed to refrain from physical
activity for 24 hours and food and caffeine intake for three
hours prior to each testing session.
Primary objectives and primary outcome measures
The primary objectives are to compare the effects of super-
vised intradialytic and home-based exercise training on
physical function and arterial stiffness. The primary out-
come measures will be outlined below. The hypothesis is
that supervised training will be superior to home-based
training because the patients will be more likely to meet
physical activity guidelines when supervised.
Physical function
Physical function will be assessed by the 6-Minute Walk
Distance (6 MWD) test. This will be performed along a
25-metre stretch of walkway in a quiet hospital corridor.
Prior to the test, all participants will undergo a short warm
up and familiarisation with the walkway. Participants will
be instructed to walk as far as they can during the six min-
utes. Participants will be allowed to stop and rest if
needed and will receive regular encouragement from the
investigator throughout the test. Participants, but not
investigators, will be blinded to all previous test results.
The secondary outcome measure for physical function is
the Timed-Up & Go (TUG) test. The time taken for partic-
ipants to stand from a seated position, walk 3-metres,
turn, and walk back to a chair, and return to the seated
position as quickly as possible, is recorded. The better of
two attempts will be recorded.
Arterial stiffness
All measures of arterial stiffness will be taken in the hour
preceding dialysis. Aortic (carotid-femoral) pulse wave
velocity (PWV) is the primary outcome measure for arte-
rial stiffness. The method involves electrocardiogram-
gated sequential applanation tonometry (SPT-301 Mikro-
Tip, Millar Instruments, Houston, Texas) of the common
carotid and femoral (groin) arteries using the foot-to-foot
method (SphygmoCor 7.01, AtCor, Sydney, Australia) as
previously described [19].
Additional secondary outcome measures include periph-
eral (carotid-radial) PWV, AIx and central blood pressures.
Peripheral PWV will be assessed as described above from
waveforms acquired at the common carotid artery and
radial artery. Central blood pressures and AIx will be esti-
mated by pulse wave analysis (PWA) involving radial
applanation tonometry performed on the non-fistula arm
using customised software (SphygmorCor 7.01, AtCor,
Sydney, Australia) with a validated [20] and reproducible
[21] generalized transfer function. In patients with a fis-
tula in both arms, the brachial artery (medial to biceps) of
the dominant arm will be used. The AIx is defined as the
difference between the 2nd and 1st central systolic peaks
expressed as a percentage of central pulse pressure[22]
Since AIx is influenced by heart rate, the SphygmoCor
software also incorporates an algorithm which adjusts AIx
to a standard heart rate of 75 beats per minute (bpm) [23].
The central waveform will be calibrated by the average of
two measures of automated brachial blood pressure byBMC Nephrology 2009, 10:2 http://www.biomedcentral.com/1471-2369/10/2
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sphygmomanometry (UA-767, A&D, Saitama, Japan)
after five minutes of supine rest.
Physical activity and self-reported health
Additional secondary outcome measures include physical
activity and self-reported health. Items from the Active
Australia Questionnaire [24] will be used to quantify the
physical activity performed by participants as previously
described [25]. Briefly, participants in the exercise groups
will be requested to include any training performed in the
previous week as part of the study in their response to the
questionnaire. The survey measures frequency, intensity
and duration of incidental and/or intentional physical
activity in the week prior to the time of testing. The total
time spent in each activity will be multiplied by an inten-
sity value (3.5 [light], 4 [moderate] and 7 [vigorous]) and
used to calculate participants' weekly physical activity in
MET.min-1.
Self-reported health will be evaluated using the Medical
Outcomes Short-Form 36-items (SF-36) Health Survey
[26]. Widely used previously in HD populations [27,28] it
includes eight independent scales and assesses physical
and mental dimensions of health.
Baseline data
The study flow is summarized in Figure 1 and the study
evaluations are outlined in Table 1. After obtaining
informed consent patients will be booked two appoint-
ments for baseline trial measures. The first of these will
occur on a dialysis day. At this visit, additional data will
be obtained from the medical records (medical history,
medications) and measures of height, weight and blood
pressure will be recorded. PWV and PWA measures will
then be made 30 minutes prior to dialysis. On the follow-
ing day subjects will return and the TUG test will be per-
formed followed by the 6 MWD. At the completion of
these tests, the investigator will explain and ask the subject
to take home two questionnaires (SF 36 and items from
Active Australia). Subjects will be asked to complete these
surveys and bring them back the next day – at their next
dialysis visit. At their next dialysis visit patients will be
informed which group they have been randomized to and
provided more information about the intervention (or
given a brochure if assigned to usual care). Data obtained
at the study visits will be transcribed onto case record
forms for entry into a specifically designed trial database.
Visits two and three
These visits will occur at approximately three and six
months after baseline. Measures and the sequence of these
measures will be identical to the baseline visit.
Adherence to exercise training
Adherence to exercise protocols will be assessed by audit-
ing training diaries. The supervisors will complete the
intradialytic participants' training diaries at each training
session. Home-based participants will complete diaries
themselves and return them at the testing sessions.
Withdrawal from study
Subjects will be withdrawn from the study at their request,
without prejudice, as documented and explained at the
Table 1: Outcome measures at baseline, 6 and 12 months
Primary Outcome Measures
Physical Function – six minute walk distance (6 MWD) test
Arterial stiffness – aortic pulse wave velocity (PWV)
Secondary Outcome Measures
Physical Function – timed up and go (TUG) test
Arterial stiffness – peripheral pulse wave velocity
Arterial stiffness – augmentation index (AIx)
Peripheral and Central Blood Pressures
Self reported health – SF 36
Physical Activity – items from the Active Australia questionnaire
Flow chart of trial Figure 1
Flow chart of trial.BMC Nephrology 2009, 10:2 http://www.biomedcentral.com/1471-2369/10/2
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time of consenting. Patients who withdraw will be invited
to consent to follow-up testing for the remainder of the
trial to enable an intention to treat data analysis.
Sample size calculation
Data from other studies indicates that 6 MWD has the
highest variability of the two primary outcome measures
(mean ± SD; PWV = 11.1 ± 3.2 [29], 6 MWD = 347 ± 147
m[30]). We assume that this will also mean that changes
in 6 MWD will be more variable than changes in PWV. We
then assume that a 10% improvement in 6 MWD will be
clinically significant. Therefore, with alpha = 0.05, and
beta = (1-0.1 = 0.9) we require 17 subjects per group.
Allowing for a 20% withdrawal rate we aim to recruit 20
patients per group.
Statistical analyses
All statistical analyses will be performed using STATA sta-
tistical software (STATA 10; Statistical data analysis; Stata
Corp; College Station; Texas, USA). Baseline and descrip-
tive data between the groups will be analysed with one-
way ANOVA. Binary categorical data will be analysed for
variability between the groups using logistic regression.
Parametric longitudinal data analysed via two-factor
(group, time) analysis of variance (ANOVA) with repeated
measures on time using general linear modeling. Weekly
physical activity (MET.min-1) will be analysed via general
linear modelling. Where statistically significant differ-
ences are identified, post hoc testing will be performed
using Holms tests to locate the means that are signifi-
cantly different. Statistical significance will be set at p <
0.05.
Discussion and conclusion
The objective of this trial is to compare a supervised intra-
dialytic training program with a home-based exercise pro-
gram and usual care. The results of this study will help
determine the efficacy of home-based exercise training in
hemodialysis patients which may be a more cost effective
way of conducting an exercise program as many dialysis
units are too crowded and busy to allow for intradialytic
exercise programs. This may help in the development of
exercise guidelines for dialysis patients. The study will also
assess whether the various exercise interventions impact
on arterial stiffness a surrogate marker of cardiovascular
morbidity in these patients.
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